Literature DB >> 26207213

The past, present and future of immunotherapy against tumor.

Tao Jiang1, Caicun Zhou1.   

Abstract

Tumor is one of the most common lethal diseases in the world. Current progress of therapy remains insufficient survival benefit. Tumor immunotherapies have been proposed for more than a century. With the improvement in the understanding of the role of the immune system in the tumorigenesis and immune response to tumor, immunotherapy has obtained a rapid development and plays the significant role in tumor therapy nowadays. This review designs to provide a general overview of immunotherapy in tumors. We will introduce the landmark events in the past research of immunotherapy and elaborate a range of strategies using different immune response mechanism, which have been demonstrated successfully and even some of them have been approved by US Food and Drug Administration (FDA) to certain tumor therapy. Finally, we will discuss the future direction of immunotherapy so that we can predict the possible and valuable strategies for future tumor therapy.

Entities:  

Keywords:  Immunotherapy; T-cell; cytokines; immune checkpoints; vaccine

Year:  2015        PMID: 26207213      PMCID: PMC4483476          DOI: 10.3978/j.issn.2218-6751.2015.01.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  83 in total

Review 1.  Adjuvant therapy after curative treatment for hepatocellular carcinoma.

Authors:  Masatoshi Kudo
Journal:  Oncology       Date:  2011-12-22       Impact factor: 2.935

Review 2.  Tumor antigens.

Authors:  J L Urban; H Schreiber
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

3.  Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.

Authors:  Ulrich Keilholz; Cornelis J A Punt; Martin Gore; Wim Kruit; Poulam Patel; Danielle Lienard; Jose Thomas; Thomas M Proebstle; Alexander Schmittel; Dirk Schadendorf; Thierry Velu; Sylvie Negrier; Ulrich Kleeberg; Frederic Lehman; Stefan Suciu; Alexander M M Eggermont
Journal:  J Clin Oncol       Date:  2005-09-20       Impact factor: 44.544

4.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

Review 5.  Dendritic-cell-based therapeutic cancer vaccines.

Authors:  Karolina Palucka; Jacques Banchereau
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

Review 6.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

7.  Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins.

Authors:  A Mazumder; E A Grimm; H Z Zhang; S A Rosenberg
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

8.  V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.

Authors:  Hirotake Tokuyama; Tomomi Hagi; Stephen R Mattarollo; Jacqueline Morley; Qiao Wang; Hang-Fai So; Hang Fai-So; Fuminori Moriyasu; Mie Nieda; Andrew J Nicol
Journal:  Int J Cancer       Date:  2008-06-01       Impact factor: 7.396

9.  Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy.

Authors:  Melissa Bersanelli; Sebastiano Buti; Roberta Camisa; Matteo Brighenti; Silvia Lazzarelli; Giancarlo Mazza; Rodolfo Passalacqua
Journal:  Cancers (Basel)       Date:  2014-09-30       Impact factor: 6.639

10.  Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).

Authors:  D McDermott; J Haanen; T-T Chen; P Lorigan; S O'Day
Journal:  Ann Oncol       Date:  2013-08-13       Impact factor: 32.976

View more
  19 in total

1.  Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment.

Authors:  Meirong Huo; Yan Zhao; Andrew Benson Satterlee; Yuhua Wang; Ying Xu; Leaf Huang
Journal:  J Control Release       Date:  2016-11-15       Impact factor: 9.776

2.  Macrophages Reprogrammed In Vitro Towards the M1 Phenotype and Activated with LPS Extend Lifespan of Mice with Ehrlich Ascites Carcinoma.

Authors:  Sergey V Kalish; Svetlana V Lyamina; Elena A Usanova; Eugenia B Manukhina; Nikolai P Larionov; Igor Y Malyshev
Journal:  Med Sci Monit Basic Res       Date:  2015-10-16

Review 3.  The Utilization of the Immune System in Lung Cancer Treatment: Beyond Chemotherapy.

Authors:  Carmen W H Chan; Stephen K W Tsui; Bernard M H Law; Winnie K W So; Fiona W K Tang; Cho-Lee Wong
Journal:  Int J Mol Sci       Date:  2016-02-25       Impact factor: 5.923

Review 4.  Recent advances in understanding hepatitis C.

Authors:  Florian Douam; Qiang Ding; Alexander Ploss
Journal:  F1000Res       Date:  2016-02-03

5.  Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer.

Authors:  Tao Jiang; Xiao Chen; Wei Zhou; Guoxin Fan; Peilin Zhao; Shengxiang Ren; Caicun Zhou; Jun Zhang
Journal:  Transl Oncol       Date:  2017-01-25       Impact factor: 4.243

Review 6.  PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.

Authors:  Michal Šmahel
Journal:  Int J Mol Sci       Date:  2017-06-21       Impact factor: 5.923

7.  Exosomes from Melatonin Treated Hepatocellularcarcinoma Cells Alter the Immunosupression Status through STAT3 Pathway in Macrophages.

Authors:  Liang Cheng; Jiatao Liu; Qingqing Liu; Yu Liu; Lulu Fan; Fang Wang; Hanqing Yu; Yuhuan Li; Lijia Bu; Xiaoqiu Li; Wei Wei; Hua Wang; Guoping Sun
Journal:  Int J Biol Sci       Date:  2017-05-16       Impact factor: 6.580

Review 8.  CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.

Authors:  Danay Saavedra; Tania Crombet
Journal:  Front Immunol       Date:  2017-03-13       Impact factor: 7.561

9.  Inhibition of Phosphorylated c-Jun NH(2)-terminal Kinase by 2',4'-dihydroxy-6-methoxy-3,5-dimethylchalcone Isolated from Eugenia aquea Burm f. Leaves in Jurkat T-cells.

Authors:  Melisa I Barliana; Ajeng Diantini; Anas Subarnas; Rizky Abdulah; Takashi Izumi
Journal:  Pharmacogn Mag       Date:  2017-10-11       Impact factor: 1.085

Review 10.  The La-Related Proteins, a Family with Connections to Cancer.

Authors:  Chara Stavraka; Sarah Blagden
Journal:  Biomolecules       Date:  2015-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.